Introduction: The World Health Organization (WHO) has recently declared the outbreak and spread of the new
strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a global pandemic. In this regard, a lot of scientific investigations and clinical trials on some existing antiviral and antibiotic drugs have been ongoing to combat this menace.
Methods: In the past, conventional drug therapy has shown irregular drug distribution, poor solubility, and low permeability
to target cells, organs, and tissues. However, Chloroquine, Hydroxychloroquine Remdesivir, Lopinavir/Ritonavir, etc. have
attracted several investigations in mono-therapeutic approaches and a combination of therapy have shown promising effects
in reducing viral loading in some SARS-CoV-2 infected patients. Never the less, the advent of nanomedicine has triggered
serious attention on drug-loaded nanoparticle as nanocarriers to deliver bioactive drug molecules to target organs with increased circulation and controlled release. Therefore, the application of nanoparticles as nanocarriers for the controlled release of antiviral drugs would improve the ease of drug administration and care of patients admitted at various health care
Conclusion: Owing to their small sizes, biocompatibility, and high encapsulation properties, nanoparticles can be utilized as
potential nanocarrier of antiviral drugs for the SARS-CoV-2 management at a reduced cost with minimal side effect in the
body system. In addition, some noticeable concerns on the ongoing management of SARS-CoV-2 pandemic in developing
nations have been presented for concerted attention.